exagen-logo-440x386-1.jpg
Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
May 11, 2022 16:06 ET | Exagen Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has...
exagen-logo-440x386-1.jpg
Exagen Announces Five-Week Campaign for Lupus Awareness Month
May 01, 2022 12:00 ET | Exagen Inc.
SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a...
exagen-logo-440x386-1.jpg
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
April 25, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022,...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in Investor Summit Group’s Q2 Conference
April 20, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2...
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
March 30, 2022 08:25 ET | Exagen Inc.
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network...
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
March 22, 2022 16:06 ET | Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as...
Exagen logo_440x386 (1).jpg
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
March 22, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum
March 09, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life...
Exagen logo_440x386 (1).jpg
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
March 08, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 02, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health,...